+Compare
MRKR
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
47.13M

MRKR Marker Therapeutics Forecast, Technical & Fundamental Analysis

a developer of cell based immune therapeutics and vaccines for cancer treatment

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for MRKR with price predictions
08:00 PM EDT Sep 19, 2023

Momentum Indicator for MRKR turns negative, indicating new downward trend

MRKR saw its Momentum Indicator move below the 0 level on September 13, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In of the 80 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for MRKR turned negative on August 25, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

MRKR moved below its 50-day moving average on September 13, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MRKR crossed bearishly below the 50-day moving average on September 08, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRKR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.476) is normal, around the industry mean (22.685). P/E Ratio (0.000) is within average values for comparable stocks, (131.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.923). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (5.084) is also within normal values, averaging (316.663).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRKR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.22B. The market cap for tickers in the group ranges from 402 to 424.75B. NVO holds the highest valuation in this group at 424.75B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was 26%, and the average quarterly price growth was 31%. APLT experienced the highest price growth at 58%, while SEEL experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was 29% and the average quarterly volume growth was 43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 86
Price Growth Rating: 63
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published General Information

General Information

a developer of cell based immune therapeutics and vaccines for cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Other Consumer Services
Address
4551 Kennedy Commerce Drive
Phone
+1 713 400-6400
Employees
67
Web
http://www.markertherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BMY59.080.30
+0.51%
Bristol-Myers Squibb Co
BLND1.19N/A
N/A
Blend Labs
CLDX26.24-0.02
-0.08%
Celldex Therapeutics
LVTX1.61-0.07
-4.17%
LAVA Therapeutics NV
TRNO58.16-2.93
-4.80%
Terreno Realty Corp

MRKR and

Correlation & Price change

A.I.dvisor tells us that MRKR and SRNEQ have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MRKR and SRNEQ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRKR
1D Price
Change %
MRKR100%
-4.30%
SRNEQ - MRKR
27%
Poorly correlated
-16.61%
FATE - MRKR
27%
Poorly correlated
-2.22%
SNPX - MRKR
27%
Poorly correlated
+1.48%
SRRK - MRKR
26%
Poorly correlated
-9.34%
MDGL - MRKR
25%
Poorly correlated
-1.18%
More

Groups containing MRKR

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRKR
1D Price
Change %
MRKR100%
-4.30%
immune
(undefined stocks)
16%
Poorly correlated
-0.41%
cancer
(undefined stocks)
14%
Poorly correlated
-1.15%
vaccines
(undefined stocks)
12%
Poorly correlated
-1.35%
consumer services
(undefined stocks)
7%
Poorly correlated
+0.95%
personal
(undefined stocks)
6%
Poorly correlated
+0.43%